VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO Italy 2022 | The potential role of MRD in treating CLL patients receiving continuous therapy

In this video, Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the potential role of measurable residual disease (MRD) in influencing treatment approaches in patients with chronic lymphocytic leukemia (CLL) receiving continuous therapy. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter